PIK3CA-Related Overgrowth Spectrum clinical trials at UCSF
2 in progress, 1 open to eligible people
PIK3CA-related overgrowth spectrum is a condition that causes unusual growth of skin, fat, and blood vessels. UCSF is running studies of a mutant-selective PI3K alpha inhibitor in children and adults. UCSF is tracking safety, dose, and imaging results during these studies.
Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation
open to eligible people ages 2 years and up
This is a 3-part Phase 2 randomized study evaluating the safety and efficacy of the mutant-selective PI3Kα inhibitor, RLY-2608, in adults and children with PIK3CA Related Overgrowth Spectrum (PROS) and malformations driven by PIK3CA mutation. Part 1 is a dose selection, Part 2 is a basket design with exploratory single-arm cohorts for various subpopulations of participants, and Part 3 is randomized, double-blinded study vs placebo.
San Francisco, California and other locations
PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum
Sorry, in progress, not accepting new patients
This is a prospective Phase II multi-center study with an initial 16-week, randomized, double-blind, placebo-controlled period, followed by two extension periods to assess the efficacy, safety and pharmacokinetics (PK) of alpelisib in pediatric and adult patients with PIK3CA-related overgrowth spectrum (PROS)
San Francisco, California and other locations
Last updated: